MaxCyte, Inc. MaxCyte, Inc. - MXCR - Vesting of RSUs and PDMR Dealing
26/03/2025 07:00
RNS Number : 3104C
MaxCyte, Inc.
26 March 2025
MaxCyte, Inc.
("MaxCyte" or the "Company")
Vesting of RSUs and PDMR Dealing
The following amendment has been made to the Publication of Vesting of RSUs and PDMR Dealing released on 26 March 2025 at 07:00 under RNS number 1474C.
The RNS did not include the number of shares of previously granted restricted stock units.
All other details remain unchanged.
The full amended text is shown below.
Rockville, Maryland - 26 March 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, announces that on 18 March 2025, as per a filing lodged with the U.S. Securities and Exchange Commission, that 20,313 shares of previously granted restricted stock units ("RSUs") vested to Douglas Swirsky, Chief Financial Officer of the Company ("Vesting"). Contemporaneously, 6,939 of the newly vested shares were sold to cover withholding tax due upon the vesting. Such "sale to cover" was automatically effected to satisfy withholding tax liabilities and does not represent a discretionary trade by Mr. Swirsky. The 20,313 new shares of Common Stock were issued pursuant to the Company's existing block admission facility and were sold by Mr. Swirsky at a price range between $3.140 and $3.215 per Common Stock ("Sale"). The sold shares represent approximately 2.2% of Mr. Swirsky's total equity and option holdings in the Company's stock capital, respectively.
Following the Vesting and Sale, Mr. Swirsky holds 13,374 shares of Common Stock representing 2.2% of the issued stock capital of the Company. Mr. Swirsky holds a further 725,000 options over Common Stock, 98,437 RSUs, and 68,750 Performance Stock Units.
The information in the tables below is provided in accordance with the requirements of the UK Market Abuse Regulation.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA | +1 415-937-5400 ir@maxcyte.com |
| Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden | +44 (0)20 7886 2500 |
| UK IR Adviser ICR Healthcre Mary-Jane Elliott Chris Welsh | +44 (0)203 709 5700 maxcyte@icrhealthcare.com |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Douglas Swirsky | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Financial Officer | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | MaxCyte Inc. | |||
| b) | LEI | 54930053YHXULRFCU991 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Common stock of $0.01 each | |||
| Identification code | US57777K1060 | ||||
| b) | Nature of the transaction | Acquisition of common stock following vesting of RSUs | |||
| c) | Price(s) and volume(s) | RSUs: | |||
| Exercise Price(s) | Volume(s) | ||||
| N/A | 20,313 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 20,313 | ||||
| - Price | N/A | ||||
| e) | Date of the transaction | 17 March, 2025 | |||
| f) | Place of the transaction | US Stock Exchange, Nasdaq | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Douglas Swirsky | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Common stock of $0.01 each | |
| Identification code | US57777K1060 | ||
| b) | Nature of the transaction | Sale of common stock to satisfy withholding tax liabilities as a condition of vesting of RSUs | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume | ||
| $3.1400 | 153 | ||
| $3.1450 | 30 | ||
| $3.1500 | 427 | ||
| $3.1550 | 74 | ||
| $3.1600 | 941 | ||
| $3.1650 | 49 | ||
| $3.1700 | 1676 | ||
| $3.1750 | 37 | ||
| $3.1800 | 904 | ||
| $3.1850 | 103 | ||
| $3.1900 | 902 | ||
| $3.1950 | 62 | ||
| $3.2000 | 497 | ||
| $3.2050 | 166 | ||
| $3.2100 | 664 | ||
| $3.2150 | 254 | ||
| d) | Aggregated information | ||
| - Aggregated volume | 6,939 | ||
| - Price | $3.1793 | ||
| e) | Date of the transaction | 18 March, 2025 | |
| f) | Place of the transaction | US Stock Exchange, Nasdaq | |
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026